Polyphenol metabolism patterns in people with type 2 diabetes
Official title: Polyphenol Metabotypes in People With Diabetes Type 2
Run by University Hospital, Ghent · NCT06810635 · Data updated 2026-11-12
This project will test whether people with type 2 diabetes process dietary polyphenols differently than age-matched people without diabetes by giving an oral polyphenol challenge and measuring blood, urine, gut transit, and microbial breakdown.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 85 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Ghent Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Ghent, East Flanders and 1 other locations) |
| Status | Recruiting |
| Started | March 4, 2026 |
| Main results expected | November 2028 |
| Study ends | December 2028 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT06810635 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 40 to 85 with BMI 18.5–30 who either have type 2 diabetes diagnosed at least two years with stable medication use or are age-matched individuals without diabetes and without major comorbidities are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have recent use of antibiotics/prebiotics/probiotics, major gastrointestinal, liver, heart, lung, or immune-suppressing conditions, other forms of diabetes, or recent major diet or medication changes are unlikely to be eligible or to benefit from the protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional observational study comparing polyphenol metabotypes between adults with long-standing type 2 diabetes and age-matched individuals without diabetes. Participants undergo an oral polyphenol challenge, fasting blood draws, timed urine collections (including 24-hour urine), transit-time measurements, and questionnaires to capture diet and medication use. The study will compare metabolite profiles and link them to gut microbial capacity to degrade polyphenols and to intestinal transit time. Findings will be analyzed to identify factors that shape polyphenol metabotypes in people with and without T2DM.
Why it matters
Potential benefit: If successful, this work could help personalize dietary or microbiome-targeted strategies to improve metabolic health in people with type 2 diabetes.
How similar studies have gone: Previous observational work has characterized polyphenol metabotypes and links to the gut microbiome, but translating these profiles into clinical interventions remains an early and developing area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * all participants * between 40-85 years * age-matched individuals without diabetes * BMI between 18.5-30 * no metabolic syndrome * persons with T2DM * at leats 2 years of clinical diagnoses of T2DM * stable medication use for at least 1 month Exclusion Criteria: * pregnancy of breastfeeding * in last month * acute use of anti/pre/probiotics * start of new drug or dietary supplements * major changes in diet * major lifestyle changes * diseases * Gastrointestinal diseases (inflammatory bowel disease) * Bariatric surgery * Other forms of diabetes (cystic fibrosis/MODY/T1DM) * Heart problems (NYHA 3/4) or previous cardiovascular events * Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis * Lung problems (COPD - GOLD 3/4), cystic fibrosis * Uncontrolled thyroid function disruption in the past 6 months * Intake of coumarin derivatives and direct oral anticoagulant medication * Anti-cancer treatment: chemo-/immunotherapy * Immonosuppressants (transplant) * Antiepileptic drugs
Where it's running
-
Department of rehabilitation sciences - UGent
Ghent, Belgium Recruiting -
Ghent University
Ghent, East Flanders, Belgium Not yet recruiting
Study contacts
- Principal investigator: Bruno Lapauw, Professor — University Hospital, Ghent
- Study coordinator: Jan Stautemas, PhD
- Email: jan.stautemas@ugent.be
- Phone: 003293328967
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lifestyle change program to help type 2 diabetes go into remission in Pakistan
This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
MWN105 injection in overweight or obese adults you may join
This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.
-
MWN109 tablets in adults with type 2 diabetes mellitus
A phase 2 trial tests MWN109 tablets versus placebo (and against active control semaglutide) to see if the medicine helps adults with type 2 diabetes lower their blood sugar.
-
Brain-heart axis in adults with type 2 diabetes
This study tests how brain activity and heart regulation relate to metabolic status in adults with type 2 diabetes to understand cognitive and functional health.
-
Digital dietary help for people on GLP-1 therapy to reach better blood sugar and weight
This trial tests whether adding a digital dietary program (NutriSteppe) to usual care helps adults on GLP-1 medications see better blood sugar control and weight results.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.